Comparing fasted and post-meal exercise in people with type 1 diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of aerobic exercise training performed in a fasted state versus after a meal in individuals with type 1 diabetes over a 12-week period. Participants will engage in exercise routines while monitoring their continuous glucose levels and insulin doses. The goal is to determine whether exercising before breakfast leads to better management of blood sugar levels and reduced insulin requirements compared to exercising after meals. This long-term comparison aims to provide insights into optimizing exercise recommendations for people with type 1 diabetes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Clinical diagnosis of type 1 diabetes for 5 or more years.
2. Treatment using an insulin pump with no change in treatment modality for \> 2 continuous months and willing to share CGM data with the research team. Insulin delivery can be managed using either manual open-loop system (non-AID) or a hybrid closed loop (AID) systems.
3. Using rapid (e.g., Aspart, Lispro or Glulisine) or ultra-rapid (e.g., FiAsp) acting insulin analogs.
4. HbA1c 7.0-9.9%.
5. Have BMI of 25 kg/m2 or above
6. Have waist circumference associated with central obesity/metabolic syndrome as per Diabetes Canada definition

   * 94cm for males of European, Sub-Saharan African, Eastern Mediterranean and Middle Eastern descent
   * 90cm for males of South Asian, Chinese, Japanese, South and Central American descent
   * 80cm for females
7. No history of stroke, myocardial infarction, or coronary artery disease
8. Not wearing implantable device such as a pacemaker, neurostimulators, aneurysm clips, metal fragments, epicardial electrodes, cochlear implants, magnetic ocular implants, penile implants, magnetic tissue expander, some types of breast implants, magnetic orthopedic implants, magnetic dental implants, hearing Aids, intravascular implants, for example VCI filters, coils, stents, cardiac septum implants, ventricular bypass devices.
9. Use a CGM in routine diabetes management.

Exclusion Criteria:

1. Major complication within the previous 3 months (e.g., severe hypoglycemia requiring assistance, diabetic ketoacidosis, or cardiovascular event).
2. Restriction in aerobic or resistance exercise due to significant diabetes complications (e.g., severe peripheral neuropathy, active proliferative retinopathy, etc.) or other type of limitations (e.g., orthopedic, severe arthritis, etc.).
3. Uncontrolled hypertension (e.g., blood pressure \>160 mmHg systolic or \>100 mmHg diastolic).
4. Implanted device, material, or having a condition contraindicated to MRI.
5. Ongoing pregnancy or breastfeeding.
6. Inability to give consent.
7. Use of an injection-based insulin therapy (ex. multiple daily injections or combined pump and injection-based delivery).

Where it's running

• University of Alberta
  Edmonton, Alberta, Canada Recruiting

Study contacts

• Principal investigator: Normand G Boule, PhD — University of Alberta
• Study coordinator: Normand Boule, PhD
• Email: nboule@ualberta.ca
• Phone: 780-492-4695

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predictive CGM with App for people with type 1 or insulin-treated type 2 diabetes

  This study tests whether using the Accu-Chek SmartGuide CGM with its Predict App can reduce fear of hypoglycemia and improve related behaviors and confidence in adults with type 1 or insulin-treated type 2 diabetes.

  Recruiting Fidam Rdc · Bad Mergentheim, Baden-Wurttemberg · NCT07814508

• Tirzepatide for type 1 diabetes patients who are overweight or obese

  This study tests whether tirzepatide can affect stomach emptying in adults with type 1 diabetes and overweight or obesity.

  Recruiting Phase 1 Eli Lilly and Company · Miami, Florida · NCT07803744

• Oral insulin vs. subcutaneous insulin in adults with type 1 diabetes

  This study tests an oral insulin tablet (SCD0503) against subcutaneous insulin and placebo to see how it behaves in the blood and helps control blood sugar in adults with type 1 diabetes.

  Recruiting Phase 1 Sam Chun Dang Pharm. Co. Ltd. · Neuss, North Rhine-Westphalia · NCT07634770

• Genetic risk score and progression to insulin in type 1 diabetes

  This study tests whether a genetic risk score can predict which people with type 1 diabetes will need insulin progression over three years.

  Recruiting Second Xiangya Hospital of Central South University · Changsha, Hunan · NCT07621445

• Home-based use of an advanced hybrid closed-loop insulin pump with telemonitoring for adults with type 1 diabetes

  This study tests whether starting an advanced hybrid closed-loop insulin pump at home, with online education and telemonitoring, is feasible and safe for adults with type 1 diabetes.

  Recruiting Air Liquide Healthcare Spain · Cartagena, Murcia and 2 other locations · NCT07492992

• Diabetes multimorbidity and a voice diary app to help self-manage

  This study tests whether the Fabla-diabetesMM audio diary app is feasible and helpful for older adults with type 1 or type 2 diabetes who also have additional chronic conditions.

  Recruiting Emory University · Atlanta, Georgia · NCT07474376

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.